SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) May 15, 2003
BARR LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
New York 1-9860 22-1927534
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519
(Address of principal executive offices) (Zip code)
(845) 362-1100
(Registrant's telephone number, including area code)
Item 5. Other Events and Regulation FD Disclosure.
On May 15, 2003, Barr Laboratories, Inc. issued a press release announcing that
the U.S. District Court for the Eastern District of New York has granted Barr's
motion to dismiss the case captioned In Re Tamoxifen Citrate Antitrust
Litigation. A copy of the release is attached hereto as Exhibit 99.0 and is
incorporated herein by reference.
Exhibit Number Exhibit
-------------- --------
99.0 Barr Laboratories, Inc. May 15, 2003 press release
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BARR LABORATORIES, INC.
Date: May 15, 2003 /s/ William T. McKee
------------------------------------------------
William T. McKee
Senior Vice President, Chief Financial Officer,
and Treasurer